An interventional study of Conservative/Expectant Management in Placenta Accreta Spectrum, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment
This study for the conservative management of placenta accreta spectrum disorders (PAS), which are a major cause of maternal morbidity and mortality. The most common management strategy for PAS in the United States is a preterm cesarean-hysterectomy. However, accumulating data show that conservative management is safer and is preferred by some patients. In selected participants (n=15) who desire uterine preservation, the investigators provide the option of conservative management, which will be defined as leaving the placenta in the uterus after delivery of the infant. This is a single-arm single-site pilot study where all participants will be carefully monitored during a standard postpartum inpatient stay and with outpatient follow-up until the uterus is empty.
150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.
This study's planned enrollment of 15 is below the median of 70 across 67 interventional studies indexed under Placenta Accreta.
Browse Placenta Accreta studies →University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 235 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 109 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conservative management of PAS with the inclusion of antibiotics and uterine artery embolization, followed by close monitoring.
Other: Conservative/Expectant Management
At time of caesarean section, participants will not have a hysterectomy, but will be treated clinically to preserve their uterus.
Hysterectomy rate
Percent of participants who undergo a hysterectomy
Time frame: Delivery through 1 year
Endometritis rate
Percent of participants who have endometritis
Time frame: Delivery through 1 year
Coagulopathy rate
Percent of participants who have coagulopathy
Time frame: Delivery through 1 year
Frequency of vaginal bleeding
Percent of participants with vaginal bleeding at each time point
Time frame: Delivery through 1 year
Frequency of pelvic pain
Percent of participants with pelvic pain at each time point
Time frame: Delivery through 1 year
Plan to share: No — Individual participant data will not be shared given the extremely small sample size and risk of participant identification
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Sep 2030, 64 months after the start.
Of 45 non-industry interventional studies with no phase under Placenta Accreta, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 64 months is above that.
Counting every sponsor, half of 45 studies reached it within 19 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.